Overview

Allopurinol Combination Study

Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
To compare the proportion of subjects whose serum urate (sUA) levels are < 6.0 mg/dL following 4 weeks of continuous treatment of RDEA594 in combination with allopurinol to allopurinol alone in subjects with documented inadequate hypouricemic response with standard doses of allopurinol.
Phase:
Phase 2
Details
Lead Sponsor:
Ardea Biosciences, Inc.
Treatments:
Allopurinol
Lesinurad